We have completed an intensive immunological and virologic analysis of asymptomatic HIV-1 infected patients who received 1 million IU of IL-2 subcutaneously every day for 12 weeks. We did not see a rise in CD4 or CD8 cells, which we attribute to the release of soluble blocking IL-2 receptors. In our second trial, we changed to intermittent therapy at the beginning of each month, and have seen much more promising effects on CD4 counts.
Showing the most recent 10 out of 461 publications